Document Detail


Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.
MedLine Citation:
PMID:  11303954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The objective of this study is to examine the intestinal permeability of novel lipophilic derivatives of DADLE (Tyr-D-Ala-Gly-Phe-D-Leu), an enkephalin analogue, using isolated rat intestinal membranes. METHODS: The novel lipophilic derivatives of DADLE were synthesized by chemical modification with various fatty acids at the C terminus. The pharmacological activities of these DADLE derivatives were assessed by a hot plate test. The intestinal permeability of these derivatives was estimated by the in vitro Ussing chamber method. RESULTS: We obtained four different DADLE derivatives including acetyl-DADLE (DADLE-C2), butyryl-DADLE (DADLE-C4), caproyl-DADLE (DADLE-C6), and caprylyl-DADLE (DADLE-C8). All the derivatives of DADLE had at least 75% of the activity of native DADLE, suggesting that chemical modification of DADLE at the C terminus did not markedly affect its pharmacological activity. These DADLE derivatives were more stable than native DADLE in jejunal and colonic homogenates. A "bell-shaped" profile was observed between the apparent permeability coefficients (Papp) of DADLE derivatives and lipophilicity. In particular, DADLE-C4 had the greatest permeability characteristics across the intestinal membrane of the acyl derivatives studied in this experiment. The permeability of DADLE-C4 across the jejunal membrane was further improved in the presence of puromycin, amastatin, and sodium glycocholate (NaGC), all at a concentration of 0.5 mM. CONCLUSIONS: We suggest that the combination of chemical modification with butyric acid and the application of a protease inhibitor are effective for improving the absorption of DADLE across the intestinal membrane.
Authors:
T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Related Documents :
16722624 - Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sod...
16207614 - Alginate-based in situ gelling suspensions and emulsions comprising n4-alkyloxycarbonyl...
1271254 - N-halo derivatives iii: stabilization of nitrogen-chlorine bond in n-chloroamino acid d...
15127794 - Biotransformation of lignin polymers derived from beech wood pulping by sporobolomyces ...
20944 - Occurrence of fatty acid chlorohydrins in jellyfish lipids.
993404 - A study of cow's milk containing high levels of linoleic acid: isolation and properties...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Pharmaceutical research     Volume:  17     ISSN:  0724-8741     ISO Abbreviation:  Pharm. Res.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-04-16     Completed Date:  2001-07-12     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8406521     Medline TA:  Pharm Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1461-7     Citation Subset:  IM    
Affiliation:
Department of Biopharmaceutics, Kyoto Pharmaceutical University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Chemistry, Physical
Colon / metabolism
Enkephalin, Leucine / analogs & derivatives*,  pharmacokinetics,  pharmacology*
Enkephalin, Leucine-2-Alanine / chemistry,  pharmacokinetics,  pharmacology*
Half-Life
Intestinal Absorption / physiology
Intestines / metabolism
Jejunum / metabolism
Lipids / chemistry
Membranes / metabolism
Physicochemical Phenomena
Rats
Chemical
Reg. No./Substance:
0/Lipids; 58822-25-6/Enkephalin, Leucine; 63631-40-3/Enkephalin, Leucine-2-Alanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of passive permeability on apparent P-glycoprotein kinetics.
Next Document:  Design and in vivo evaluation of an oral delivery system for insulin.